CClinicalTrials.gg
CompletedNCT03585790Updated Jan 7, 2020Results posted

The Impact of Soft Contact Lens Attributes on Symptoms Associated With Digital Eye Strain in Symptomatic Soft Contact Lens Wearers

An interventional study of Contact lens with Multifocal Optics and Contact lens with Single Vision Optics in Asthenopia and Myopia, sponsored by Pete Kollbaum, OD, PhD. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-07.

Sponsored by Pete Kollbaum, OD, PhD · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

Despite its prevalence, the ocular causes of eye fatigue or unknown and may be related to the cornea/contact lens surface, the accommodative system, the convergence system, overall postural/muscle fatigue, or a combination of these or other causes. The current study aims to systematically investigate the incremental benefits in ameliorating eye fatigue.

02

Conditions studied

  • Asthenopia
  • Myopia

Browse trials for

Keywords

  • Eye Fatigue
03

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Self-reported "eye fatigue" at least once per week attributable to digital device use with baseline.
  2. Uses a digital device (phone, tablet, computer, etc) at least 4 hours per day
  3. Mobile digital device with active data and text plan, able to receive email and text messages
  4. Habitual 2-week or monthly silicone single vision hydrogel soft contact lens use; habitually wearing lenses for 6 or more hours per day for 5 or more days per week for the past 30 days
  5. Habitual soft contact lens prescription optimized over-refraction within ±0.25 D
  6. 18-35 years of age
  7. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  8. Vertex corrected refractive cylinder must be -0.75 or less.
  9. Visual acuity best correctable to 20/25 or better for each eye
  10. The subject must read and sign the Informed Consent form.

Exclusion criteria

Exclusion Criteria:

  1. A habitual wearer of any of the test lenses
  2. Any active conditions that may prevent soft contact lens wear.
  3. Any doctor diagnosed, self-reported ocular surface disease or dry eye requiring regular, ongoing treatment
  4. Any doctor diagnosed, self-reported accommodative or binocular vision issues
  5. History of issues of eye alignment or binocularity by self-report
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
45 participants (actual)

Study arms

  • Other
    Multifocal Optics first, then Single Vision Optics

    First Intervention (1 week) Second Intervention (1 week)

    Device: Contact lens with Multifocal Optics · Device: Contact lens with Single Vision Optics

  • Other
    Single Vision Optics first, then Multifocal Optics

    First Intervention (1 week) Second Intervention (1 week)

    Device: Contact lens with Multifocal Optics · Device: Contact lens with Single Vision Optics

Interventions

  • DeviceContact lens with Multifocal Optics

    This contact lens has optics to aid the accommodative and convergence systems

  • DeviceContact lens with Single Vision Optics

    This contact lens has standard single vision optics

05

What researchers measure

Primary outcomes

  1. Subject Reported Eye Fatigue

    Subjective Rating of Eye Fatigue, response to question "How would you rate your overall eye fatigue/tiredness?" on a 0-100 slider visual analog scale, where 0 represents 'Not Noticeable' and 100 represents 'Very Noticeable', with the numerical representation of their visual analog selection displayed to the right of the slider scale. Score reported is rating as described above.

    Time frame: 1 week

06

Results

Posted Jan 7, 2020

Participant flow

First Intervention (1 Week)
Participant flow — First Intervention (1 Week)
MilestoneMultifocal Optics First, Then Single Vision OpticsSingle Vision Optics First, Then Multifocal Optics
Started2322
Completed2322
Not completed00
Second Intervention (1 Week)
Participant flow — Second Intervention (1 Week)
MilestoneMultifocal Optics First, Then Single Vision OpticsSingle Vision Optics First, Then Multifocal Optics
Started2322
Completed2322
Not completed00

Outcome measures

PrimarySubject Reported Eye Fatigue

Subjective Rating of Eye Fatigue, response to question "How would you rate your overall eye fatigue/tiredness?" on a 0-100 slider visual analog scale, where 0 represents 'Not Noticeable' and 100 represents 'Very Noticeable', with the numerical representation of their visual analog selection displayed to the right of the slider scale. Score reported is rating as described above.

Time frame:
1 week
Reported as:
Median · units on a scale
Subject Reported Eye Fatigue
units on a scaleMultifocal Optics First, Then Single Vision OpticsSingle Vision Optics First, Then Multifocal OpticsTotal
Single Vision18 (6.5 to 39)21 (15.25 to 48)21 (11 to 45)
Multifocal17 (6.5 to 33.5)21.5 (16.75 to 38.75)20 (8 to 38)
Statistical analysis
  • Multifocal Optics First, Then Single Vision Optics · t-test, 1 sided · p = 0.18

Adverse events

Collected over through study completion, an average of 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Multifocal Optics First, Then Single Vision Optics0/23 (0%)0/23 (0%)0/23 (0%)
Single Vision Optics First, Then Multifocal Optics0/22 (0%)0/22 (0%)0/22 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Multifocal Optics First, Then Single Vision OpticsSingle Vision Optics First, Then Multifocal OpticsTotal
<=18 years000
Between 18 and 65 years232245
>=65 years000
Age, Continuous
Age, Continuous(years)Multifocal Optics First, Then Single Vision OpticsSingle Vision Optics First, Then Multifocal OpticsTotal
Mean21.87 ± 3.3722.5 ± 3.0122.17 ± 3.25
Sex: Female, Male
Sex: Female, Male(Participants)Multifocal Optics First, Then Single Vision OpticsSingle Vision Optics First, Then Multifocal OpticsTotal
Female191635
Male4610
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Multifocal Optics First, Then Single Vision OpticsSingle Vision Optics First, Then Multifocal OpticsTotal
Hispanic or Latino145
Not Hispanic or Latino221840
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Multifocal Optics First, Then Single Vision OpticsSingle Vision Optics First, Then Multifocal OpticsTotal
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American011
White211637
More than one race022
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Multifocal Optics First, Then Single Vision OpticsSingle Vision Optics First, Then Multifocal OpticsTotal
United States232245
07

Study locations

1 site
  • Indiana University Clinical Optics Research Lab
    Bloomington, Indiana 47405, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 8, 2017

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03585790
Lead sponsor
Pete Kollbaum, OD, PhD
Collaborators
Alcon Research
Responsible party
Pete Kollbaum, OD, PhD (Principal Investigator, Indiana University) — Sponsor-investigator
First posted
Jul 13, 2018
Start date
Sep 13, 2018
Primary completion
Nov 2, 2018
Completion
Nov 2, 2018
Results posted
Jan 7, 2020
Last update
Jan 7, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion